SPONSORED FEATURE
Guiding treatment decisions for patients with advanced stage cancer with a simple blood draw
Guardant Health ’ s non-invasive liquid biopsy test helps identify appropriate therapy options in approximately seven days upon sample receipt in the laboratory .
The
®
Guardant360 test is Guardant Health ’ s breakthrough liquid biopsy for patients with advanced stage cancer . This test is done using circulating tumor DNA ( ctDNA ), which is produced when tumors shed small pieces of their genetic material into the bloodstream . Traces of this ctDNA can be detected in the blood using digital sequencing technology . Over 70 clinically relevant genes are examined in the test to identify genomic alterations within a patient ’ s cancer DNA . This helps oncologists understand which alterations exist in a patient ’ s cancer without the complications and delays of a tissue biopsy . With just a simple and noninvasive blood draw from the patient , oncologists will be able to see test results in approximately one week from sample receipt in the laboratory . With this fast and reliable comprehensive genomic profiling information about the patient ’ s tumor , oncologists can recommend appropriate treatment for their patients sooner .
150,000 + Clinical Samples Reported |
60 + Biopharma Partners |
9,000 + Ordering Oncologists |
|
200 +
Peer-reviewed publications
|
A few words from our CEO , Guardant Health AMEA
“ Time to treatment is crucial for patients with advanced stage cancer . With just a simple blood draw , the Guardant360 liquid biopsy test allows oncologists to see the current genomic profile of their patient ’ s tumor in approximately seven days and recommend appropriate treatment sooner . This FDA-approved liquid biopsy is highly validated by over 200 peer-reviewed publications and has shown high agreement with tissue biopsies in detecting actionable mutations . You can now choose to avoid the delays and complications of tissue biopsies . Test your patients with Guardant360 today , get comprehensive genomic profiling information about their tumor and take action by matching your patients to suitable therapies quickly .”
Simranjit Singh Chief Executive Officer Guardant Health Asia , Middle East & Africa
24 AUGUST 2021 GlobalHealthAsiaPacific . com